Increasing evidence suggests that B cells play a critical role in the pathogenesis of multiple sclerosis (MS). Rituximab (RTX), a monoclonal anti-CD20 antibody, effectively decreases inflammatory disease processes in patients with MS by specifically removing B cells. Neutropenia is an uncommon side effect of CD20-depleting treatment and may require the administration of granulocyte-colony stimulating factors. We report the case of a patient with MS who experienced severe neutropenia during RTX treatment.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: